← Back to Search

Other

Uridine for Suicidal Thoughts

Phase 4

Waitlist Available

Led By Douglas Gavin Kondo, MD

Research Sponsored by VA Office of Research and Development

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Females and Males Ages 18-55 Inclusive

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks

Awards & highlights

Study Summary

This trial will test whether the supplement uridine can reduce suicidal thoughts in veterans.

Who is the study for?

This trial is for U.S. veterans aged 18-55 with suicidal thoughts, who have attempted suicide or been hospitalized to prevent it in the past year, or have significant suicidal ideation not due to a personality disorder. They must consent and provide an emergency contact but cannot join if pregnant, breastfeeding, unable to undergo MRI scans, dealing with severe substance abuse needing stabilization, having unstable health conditions, participating in another trial or at risk of non-adherence.Check my eligibility

What is being tested?

The study tests whether uridine (a dietary supplement) can reduce suicidal thoughts over four weeks compared to a placebo. Veterans are randomly assigned to either receive uridine or a placebo without knowing which one they're getting (double-blind). The effectiveness of uridine is measured against the placebo control group.See study design

What are the potential side effects?

Specific side effects are not listed here; however, as with any clinical trial involving new treatments like uridine supplementation for mental health conditions such as suicidal ideation, participants may experience unexpected reactions that will be monitored throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Genes, Transgenic, Suicide

Secondary outcome measures

Brain

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: UridineActive Control1 Intervention

Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks

Group II: PlaceboPlacebo Group1 Intervention

Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor

1,609 Previous Clinical Trials

3,306,528 Total Patients Enrolled

Douglas Gavin Kondo, MDPrincipal InvestigatorVA Salt Lake City Health Care System, Salt Lake City, UT

Media Library

Uridine (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03265964 — Phase 4

Suicidal Thoughts Research Study Groups: Uridine, Placebo

Suicidal Thoughts Clinical Trial 2023: Uridine Highlights & Side Effects. Trial Name: NCT03265964 — Phase 4

Uridine (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03265964 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age eligibility limit for this trial under sixty years?

"Eligibility for this trial requires that participants are 18 years of age or older, but not beyond the upper limit of 55."

Answered by AI

Are there any opportunities to participate in this research endeavor?

"Affirmative, the clinical trial is searching for volunteers. It was first posted on April 2nd 2018 and most recently updated on April 21st 2022. The team needs to source 90 participants from a single location."

Answered by AI

Has the U.S. Food and Drug Administration (FDA) accepted Uridine for therapeutic programming?

"A score of 3 was assigned to Uridine due its status as a Phase 4 trial, which indicates that it has been approved for medical use."

Answered by AI

How many people have been recruited to participate in this clinical research?

"Affirmative. Clinicaltrials.gov records indicate that this clinical trial, which commenced on April 2nd 2018, is currently enrolling patients. Approximately 90 participants are sought from a single medical site."

Answered by AI

What other experiments have been conducted using Uridine as a subject of investigation?

"Currently, there is 1 active research project for Uridine and none of them are in their last phase. Most of these investigations are held in Salt Lake City, Utah but one other location has been identified as a potential site."

Answered by AI

Is there an opportunity for me to volunteer in this medical experiment?

"To be included in the trial, potential participants must display suicidal behaviour and be between 18 to 55 years old. The study expects approximately 90 individuals will meet this criteria."

Answered by AI

Recent research and studies

NeuropsychopharmacologyJournal

Neurochemical Alterations in Methamphetamine-dependent Patients Treated with Cytidine-5′-diphosphate Choline: A Longitudinal Proton Magnetic Resonance Spectroscopy Study

Yoon, Sujung J, In Kyoon Lyoo, Hengjun J Kim, Tae-Suk Kim, Young Hoon Sung, Namkug Kim, Scott E Lukas, and Perry F Renshaw. 2009. “Neurochemical Alterations in Methamphetamine-dependent Patients Treated with Cytidine-5′-diphosphate Choline: A Longitudinal Proton Magnetic Resonance Spectroscopy Study”. Neuropsychopharmacology. Springer Science and Business Media LLC. doi:10.1038/npp.2009.221.

Neuroscience ResearchJournal

Gene Expression Profiling of Major Depression and Suicide in the Prefrontal Cortex of Postmortem Brains

Tochigi, Mamoru, Kazuya Iwamoto, Miki Bundo, Tsukasa Sasaki, Nobumasa Kato, and Tadafumi Kato. 2008. “Gene Expression Profiling of Major Depression and Suicide in the Prefrontal Cortex of Postmortem Brains”. Neuroscience Research. Elsevier BV. doi:10.1016/j.neures.2007.10.010.

Biological PsychiatryJournal

Antidepressant-like Effects of Uridine and Omega-3 Fatty Acids Are Potentiated by Combined Treatment in Rats

Carlezon, William A., Jr., Stephen D. Mague, Aimee M. Parow, Andrew L. Stoll, Bruce M. Cohen, and Perry F. Renshaw. 2005. “Antidepressant-like Effects of Uridine and Omega-3 Fatty Acids Are Potentiated by Combined Treatment in Rats”. Biological Psychiatry. Elsevier BV. doi:10.1016/j.biopsych.2004.11.038.

Bipolar DisordersJournal